The Mutation of BTG2 Gene Predicts a Poor Outcome in Primary Testicular Diffuse Large B-Cell Lymphoma
Dan Guo,Lemin Hong,Hao Ji,Yuwen Jiang,Ling Lu,Xinfeng Wang,Hongming Huang
DOI: https://doi.org/10.2147/JIR.S341355
IF: 4.5
2022-03-10
Journal of Inflammation Research
Abstract:Dan Guo, 1, &ast Lemin Hong, 1, &ast Hao Ji, 2, &ast Yuwen Jiang, 1 Ling Lu, 1 Xinfeng Wang, 1 Hongming Huang 1 1 Department of Hematology, The Affiliated Hospital of Nantong University, Jiangsu, People's Republic of China; 2 Department of Urology, Tumor Hospital Affiliated to Nantong University, Nantong, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xinfeng Wang; Hongming Huang, Department of Hematology, The Affiliated Hospital of Nantong University, No. 20, Xisi Street, Nantong, 226001, Jiangsu, People's Republic of China, Email ; Introduction: Primary testicular diffuse large B-cell lymphoma (PT-DLBCL) is a rare and aggressive form of mature B-cell lymphoma commonly found in elder males, but its genetic features are poorly understood. In this study, we had performed target-sequencing of 360 lymphoma-related genes on 76 PT-DLBCL patients with a median age of 65 (33– 89). Our data provide a comprehensive understanding of the landscape of mutations in a small subset of PT-DLBCL. Methods: A total of 76 PT-DLBCL patients were sequenced, and their clinical data and follow-up data were collected. The relationship between mutated genes, clinical data and prognosis and survival of PT-DLBCL patients was retrospectively analyzed by statistical software. Results: We observed a median of 15 protein-altering variants per patient in our data and was identified recurrent oncogenic mutations of 360 lymphoma-related genes involved in PT-DLBCL, including PIM1 (74%), MYD88 (50%), KMT2D (38%), KMT2C (34%), BTG2 (34%), TBL1XR1 (34%) and ETV6 (24%). Compared with classic DLBCL, PT-DLBCL showed an increased mutation frequency of PIM1, MYD88, BTG2 , while NOTCH1 appeared exclusive mutated with PIM1, MSH3 and ETV6 . Cox risk model regression analysis showed that age ≥ 60 years, IPI 3– 5 points, BTG2 gene mutation and extranodal organ invasion suggested poor prognosis. Finally, we constructed an OS predict model of PT-DLBCL patients using above factors with a high accuracy. Conclusion: In conclusion, our results revealed genomic characterization of PT-DLBCL, and the mutation of BTG2 was an independent factor predicting a poor prognosis. Keywords: primary testicular diffuse large B-cell lymphoma, genetic mutation, BTG2 , prognosis, survival Primary testicular diffuse large B-cell lymphoma (PT-DLBCL) is a rare and aggressive form of mature B-cell lymphoma. 1–3 PT-DLBCL was the most common type of testicular tumor in men aged over 60 and characterized by painless uni- or bilateral testicular masses with infrequent constitutional symptoms. 4–6 PT-DLBCL shows significant extranodal tropism, and features a high risk of recurrence in the central nervous system (CNS) and contralateral testis, directly leading to poor prognosis. 7,8 Although the addition of radiotherapy, whole-course chemotherapy, CNS-directed prophylaxis and rituximab have greatly improved the prognosis of DLBCL patients, 9–11 the biomarkers of prognosis remains poor for PT-DLBCL. Gene expression profiling had demonstrated that PT-DLBCL showed phenotypic similarities with nodal DLBCL of activated B-cell-like (ABC) origin. 12–14 Research based on small samples found that mutations of TP53 and C-MYC as well as BCL2 rearrangements were rare in PT-DLBCL, whereas BCL6 was commonly rearranged and CXCR4 might be the prognostic marker for PT-DLBCL. 15,16 Chapuy et al have found that although patients with PT-DLBCL had few TP53 mutations compared with systemic DLBCL ones, but the P53 pathway had always been interfered via disorders of upstream signals, usually double-allelic CDKN2A deletion. 17 Moreover, patients with central nervous system lymphoma (PCNSL) and primary testicular lymphoma (PTL) were observed with high-frequent mutation of CD79B, MYD88L265P, ETV6, PIM1 and TBL1XR1 mutations, as well as poor prognosis. 18,19 However, due to the rarity of PT-DLBCL (approximately 1–2% of cases and rarity of specimen), 20 the genetic features of PT-DLBCL had not been understood well, and the effects of gene mutation on the prognosis were still unclear. Previous studies have shown that type B symptoms, advanced neuronal cell necrosis (III/IV), and extra node involvement were poor prognostic markers for PT-DLBCL. 21–26 Retrospective studies had shown that the prognostic roles of IPI may be surrogate indicators of -Abstract Truncated-
immunology